Register
FDA approves Revcovi for adenosine deaminase severe combined immune deficiency |
Journal Updates
eMediNexus Coverage from: 
FDA approves Revcovi for adenosine deaminase severe combined immune deficiency
eMediNexus,  10 October 2018
remove_red_eye 471 Views
#Pathology and Lab Medicine #Pharmacist

0 Read Comments                

The US Food and Drug Administration (FDA) has approved elapegademase-lvlr (Revcovi, Leadiant Biosciences) for the treatment of adults and children with adenosine deaminase severe combined immune deficiency.
To continue reading this article
Or

Continue reading your article with a Emedinexus account..
Free Membership!